Methods of treating an overweight or obese subject

Patent metadata

Field	Value
Publication number	US-9656979-B2
Application number	US-201514616002-A
Country	US
Kind code	B2
Filing date	Feb 6, 2015
Priority date	Dec 4, 2008
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAp-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.

First claim

What is claimed is:

1. A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula C-D wherein C is represented by:

and D is represented by:

wherein:
Z, R and Y are not present;
X is C 1-6 alkyl;
P is a moiety selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A method of treating a subject having an overweight or obese condition, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of:

and a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein the subject has a Body Mass Index measurement selected from the group consisting of: at least about 25 kg/m 2 , at least about 30 kg/m 2 , and at least about 40 kg/m 2 .

4. The method of claim 2 , wherein the pharmaceutical composition is administered non-parenterally.

5. The method of claim 2 , wherein the pharmaceutical composition is administered parenterally.

6. The method of claim 2 , wherein the pharmaceutical composition is administered subcutaneously.

7. A method for controlling hepatic steatosis in an obese subject being treated for obesity, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of:

and a pharmaceutically acceptable salt thereof.

Assignees

• Zafgen Inc

Inventors

• Vath James E

Classifications

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• C07D303/22 Primary

  with monohydroxy compounds · CPC title

• A61K31/336

  having three-membered rings, e.g. oxirane, fumagillin · CPC title

• A61K31/439

  the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title

• C07D453/02

  containing not further condensed quinuclidine ring systems · CPC title